Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

TSXV:CZO - Post Discussion

Ceapro Inc > shareholder value destruction, let's keep it simple
View:
Post by Ciao on Dec 23, 2023 11:02am

shareholder value destruction, let's keep it simple

let's looks at the track record via the stock chart

[url=https://www.google.com/finance/quote/AEZS:NASDAQ?hl=en&window=MAX]https://www.google.com/finance/quote/AEZS:NASDAQ?hl=en&window=MAX[/url]

and you one can pull out all the previous news releases on AEZS and see how their pipeline is a cash burning machine with share rollbacks of 25 to 1 (in 2022) and 100 to 1 (in 2015 as shares had ballooned to 544M shares) after issuing decades of cheap paper

and how Gilles as CEO of AEZS led the share price to a 80% decline, and when he returned as a board member in January 1 2020 (yes he was there for the $1.45 financing in 2021 and a year later for the 1 for 25 share consolidation) to present, the share price has dropped another 96%

and now Gilles wants to return as the CEO where essentially he wants to sell an ongoing concern, CEAPRO at a liquidation value using paper shares, where they will tout PGX to raise funds by issuing more paper shares as the Macimorelin story is old and tired

https://www.biospace.com/article/releases/effective-immediately-aeterna-zentaris-ceo-out-and-new-leader-named-special-committee-formed-to-review-options-/

and 6 years after a special committee could not do anything to enhance shareholder value, and where the share price since then has dropped on July 28, 2017 at $54 USD to the current $2 USD

and one can see that the lack of insider holdings / buys shows they don't believe in the company,
this merger benefits the management team at AEZS and 5 new CEAPRO board members who will join the new company with funds to keep their salaries and company going, this merger does not benefit CEAPRO shareholders

and Gilles will attempt to escape accountability where CEAPRO shareholders have been calling for him to be removed from the board for years (sharesholders failed to get a majority vote at the last few AGMs) and for him to be replaced as the CEO for his lack of intergrity and years of failures while "working" remotely in Sherbrooke and under friendly board members (a model he has duplicated with the new proposed board)

Say NO to this SHAM merger
Comment by Ciao on Dec 23, 2023 11:04am
let's try the chart again [url=https://www.google.com/finance/quote/AEZS:NASDAQ?hl=en&window=MAX]https://www.google.com/finance/quote/AEZS:NASDAQ?hl=en&window=MAX[/url]
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities